Pharmacyclics, Inc., a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company's principal development products include Xcytrin injection, an anti-cancer agent that is in phase II clinical trials; and Histone Deacetylase Inhibitor, a phase I clinical trial product that targets histone deacetylase enzymes and inhibits their function. Its other development products comprise HDAC-8 selective inhibitor, a preclinical stage drug for the treatment of cancer; a small molecule inhibitor of Factor VIIa, which has demonstrated anti-angiogenic and anti-cancer activity in the laboratory and inhibitors of tyrosine kinase enzymes; and B cell associated tyrosine kinase inhibitors for the treatment of lymphomas and autoimmune diseases. The company has a collaboration and license agreement with the National Cancer Institute. Pharmacyclics was founded in 1991 and is headquartered in Sunnyvale, California.
We are leveraging our small-molecule drug development expertise to build a pipeline in oncology and immune mediated diseases based on novel targets, pathways and mechanisms. We have several products in the pipeline, each derived from structure-based research. Multiple histone deacetylase (HDAC) inhibitors, both broad spectrum (PCI-24781) - meaning they target all forms of HDAC enzymes - and isoform selective (HDAC8), are being developed for solid tumors and lymphomas. Our Factor VIIa inhibitor, PCI-27483, possesses a novel mechanism of action that targets both the tumor itself and thrombotic disease that often occurs in patients with cancer. Finally, our lead BTK inhibitor PCI-32765 shows promising activity in animal models of lymphoma and rheumatoid arthritis.